Although pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, has had beneficial effects on lipid metabolism, inflammation, and oxidative stress, its impact on zinc metabolism in patients with metabolic dysfunction-associated steatohepatitis (MASH) remains unclear.<h4>Methods</h4>This prospective study involved patients with biopsy-confirmed MASH complicated by hypertriglyceridemia (fasting triglycerides ≥ 150 mg/dL) who were treated with pemafibrate (0.2 mg twice daily). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.